- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06926790
Nivolumab neoadyuvante más ipilimumab en resecable NSCLC (Galaxy 3) (GALAXY 3)
Nivolumab neoadyuvante más ipilimumab en cáncer de pulmón de células no pequeñas resecables
Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).
Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Shuben Li, Professor
- Número de teléfono: 020-8306-2114
- Correo electrónico: 13500030280@163.com
Ubicaciones de estudio
-
-
-
Guangzhou, Porcelana, 510120
- Reclutamiento
- First Affiliated Hospital of Guangzhou Medical University
-
Contacto:
- Shuben Li, PHD
- Número de teléfono: +8613925810521
- Correo electrónico: 13500030280@163.com
-
Contacto:
- Jiawei Chen, PHD
- Número de teléfono: +8613925810521
- Correo electrónico: m13925810521@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Informed consent must be signed.
- At least 18 years of age.
- Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
- Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
- disease eligible for surgery.
- No previous systematic therapy or radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least one measurable lesion.
- No major organ dysfunction, including liver, kidney, and cardiac function.
Exclusion Criteria:
- Patients with active autoimmune disease or history of autoimmune disease.
- Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
- History of allergy to study drug components.
- Pregnant or breast-feeding.
- Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
- Patients who have other malignancies.
- History of major surgery or serious injury within the past 3 months.
- HIV, HBV, HCV infection or active pulmonary tuberculosis.
- Vaccination within 4 weeks prior to the start of the study.
- Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Neoadjuvant treatment
Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week). Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy. After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor. |
This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pathological Complete Response (PCR)
Periodo de tiempo: Within 2 weeks after surgery
|
Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes. |
Within 2 weeks after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
3-year Event-Free Survival (3-year EFS)
Periodo de tiempo: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
|
The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up. |
From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
|
|
Major Pathological Response (MPR)
Periodo de tiempo: Within 2 weeks after surgery
|
Major pathological response defined as less than 10% of viable tumor cells in primary tumor. |
Within 2 weeks after surgery
|
|
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
Periodo de tiempo: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
|
Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). |
Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
|
|
Radiological Response
Periodo de tiempo: Between the last dose of neoadjuvant treatment and surgery
|
Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. |
Between the last dose of neoadjuvant treatment and surgery
|
|
Postoperative complications
Periodo de tiempo: After the surgery assess to 90 days
|
Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes. |
After the surgery assess to 90 days
|
|
Intraoperative bleeding
Periodo de tiempo: Up to approximately 20 weeks
|
Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid. |
Up to approximately 20 weeks
|
|
The Quality of Life
Periodo de tiempo: From the Day 1 to at least 90 days after surgery
|
The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome. |
From the Day 1 to at least 90 days after surgery
|
|
Duration of surgery
Periodo de tiempo: Up to approximately 20 weeks
|
Duration of surgery is the time spent in surgery. |
Up to approximately 20 weeks
|
|
Hospital Stay
Periodo de tiempo: Up to approximately 20 weeks
|
Hospital Stay is the length of inpatient time spent in hospital. |
Up to approximately 20 weeks
|
|
Feasibility (Completion rate of neoadjuvant treatment and surgery)
Periodo de tiempo: From date of treatment allocation until surgery, assessed up to 5 months
|
Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment |
From date of treatment allocation until surgery, assessed up to 5 months
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Neoplasias Pulmonares
- Carcinoma de pulmón de células no pequeñas
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Nivolumab
- Ipilimumab
Otros números de identificación del estudio
- ES-2025-027-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .